Eton Pharmaceuticals, Inc.
NASDAQ:ETONBiotechnology
-$0.46 today
- Market cap
- $1.79B
- Beta
- 0.89
- P/E (TTM)
- -597.6
- EPS (TTM)
- -$0.05
Volume 0.48M
Average 0.43M
Returns on capital
Eton Pharmaceuticals, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-17.6%
avg -64.3%
ROIC
0.1%
avg -44.0%
ROA
-5.0%
avg -40.9%
Analysis
ROIC is currently the strongest return metric at 0.1% versus its period average of -44.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Sean E. Brynjelsen | President, Chief Executive Officer & Director | USD 1.08M | 54 | — | — |
James R. Gruber | Consultant | USD 740.51K | 54 | 213.42K | 0.78% |
David Krempa | Chief Business Officer | USD 737.19K | 37 | 43.38K | 0.16% |
Ipek Erdogan-Trinkaus | Chief Commercial Officer | USD 575.29K | 44 | 4.08K | 0.01% |
Danka Radosavljevic | Chief Operating Officer | — | 42 | 7.19K | 0.03% |
Judith Matthews | Chief Financial Officer & Secretary | — | 56 | — | — |
Scott Grossenbach | Senior Vice President of Sales Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 10, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
33
$32.05M
Net Transaction Value
−$32.05M
Net selling
Most Active
Opaleye Management Inc.
9 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 10, 26Nov 10, 2026 | Erdogan-Trinkaus Ipek Direct | Sell | $157.2K$157,198.16 |
| Nov 10, 26Nov 10, 2026 | Erdogan-Trinkaus Ipek Direct | Sell | $78.7K$78,739.06 |
| Nov 10, 26Nov 10, 2026 | CASAMENTO CHARLES J Direct | Sell | $410.4K$410,417.11 |
| Nov 10, 26Nov 10, 2026 | CASAMENTO CHARLES J Direct | Sell | $961.3K$961,255.90 |
| Nov 10, 26Nov 10, 2026 | CASAMENTO CHARLES J Direct | Sell | $1.5M$1,497,576.16 |
| Nov 10, 26Nov 10, 2026 | CASAMENTO CHARLES J Direct | Sell | $2.3M$2,278,797.35 |
| Nov 10, 26Nov 10, 2026 | CASAMENTO CHARLES J Direct | Sell | $197K$197,025.16 |
| Oct 6, 26Oct 6, 2026 | Krempa David Direct | Sell | $229.4K$229,406.21 |
| Aug 28, 26Aug 28, 2026 | MAIER PAUL V Direct | Sell | $811.9K$811,931.85 |
| Aug 28, 26Aug 28, 2026 | MAIER PAUL V Direct | Sell | $7.9K$7,906.56 |
1–10 of 33
Summary
Insiders reported 0 buys worth $0.00 and 33 sells worth $32.05M over the last 12 months. That adds up to net selling of $32.05M. Opaleye Management Inc. was the most active insider with 9 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +55.5% | +46.0% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | +406.3% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +55.5% over three years. Forward estimates point to EBIT at +406.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Eton Pharmaceuticals, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ETON's management, answered from reported figures.
Who manages ETON?
Eton Pharmaceuticals, Inc. (ETON) lists 7 active executives. The top listed executive is David Krempa, Chief Business Officer.
Are ETON insiders buying or selling?
Recent insider activity shows net selling of $18.54M.
Continue the stock analysis
Jump to another research area for this company.